MindBio Therapeutics Deploys AI Voice Analytics for Non-Invasive Intoxication Detection

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is developing artificial intelligence-based voice analysis technology to detect drug and alcohol intoxication without requiring invasive breath, saliva, or laboratory testing. The company's platform analyzes over 140 acoustic markers and is trained on more than 50 million data points to estimate impairment levels from short voice samples.

The global alcohol and drug testing devices market is projected to grow from $2.5 billion in 2025 to $4.2 billion by 2033, reflecting rising safety requirements and stricter regulatory oversight. MindBio's technology is applicable to both workplace and non-workplace settings, with an initial commercial focus on the mining industry, particularly in South America, where large workforces and high-risk operating environments create demand for rapid impairment screening. Other potential applications include aviation, construction, call centers, law enforcement, and mental health settings where high-volume screening is expensive and time-consuming.

The market for workplace drug and alcohol detection is expanding as employers face increasing pressure to improve safety while reducing the cost and friction of traditional testing methods. This creates a unique opportunity for companies attempting to modernize a process that remains heavily dependent on breathalyzers, urine testing, and laboratory analysis. MindBio Therapeutics is positioning itself in that space with an alternative approach: using artificial intelligence and voice analytics to estimate drug and alcohol intoxication levels from short speech samples. The company has spent several years conducting research and development to refine its platform.

For more information, visit the company's newsroom at https://ibn.fm/MBQIF.